Paper: Governments' and Physicians' Opposing Views on Rx Value Could Complicate Patient Care
Differing approaches to medication value may undermine patient-centered care as the Inflation Reduction Act allows officials to negotiate some Medicare Rx prices
WASHINGTON, Aug. 30, 2023 /PRNewswire/ -- Government officials and physicians don't always agree on the value of prescription drugs, a new paper from the Alliance for Patient Access explains, and the discrepancy could impact patient care when U.S. officials begin price negotiations for certain Medicare drugs as authorized by the Inflation Reduction Act.
About the Research
To examine discrepancies in medication value, researchers asked 350 U.S. physicians to respond to a European government's assessments of certain drugs for three conditions: ulcerative colitis, psoriatic arthritis and multiple myeloma.
The research used metrics from Germany's Federal Joint Committee, or G-BA, the centralized decision-making body in Germany's health care system.
Key Findings
Only 10% of U.S. physicians agreed with the G-BA's negative assessments of the innovative medications. And the overwhelming majority ? 90% ? said the medications had additional benefits for patients.
The gap suggests that physicians and government agents approach the question of value differently, the paper explains. Physicians are likely to also consider real-world factors such as:
Unmet needs
A medication's ability to prolong life expectancy until the next treatment is available
The method and frequency of drug administration
Indirect benefits, such as allowing patients or caregivers to continue working
The research echoes similar findings from 2019, when 89% of surveyed U.S. physicians disagreed with the G-BA's negative evaluation of innovative diabetes medications and 97% said the medications offered additional value for patients.
Physicians consider the nuances of their patient's diagnosis, comorbidities, health history and lifestyle, the paper notes. Government agents take a more systemwide, population-health approach.
Implications for Patient Care
Establishing drug prices based solely on a government definition of value could create challenges for patients, such as:
Inability to access new treatment if insurance plans make certain drugs harder to access.
Less personalized care as physicians feel compelled to make treatment decisions based primarily on cost.
More frequent non-medical switching, where health plans drive stable patients from effective treatment to a more profitable alternative, triggering side effects and re-emerging symptoms.
Less research and medical innovation, with experts predicting that 135 fewer new drugs will come to market over the next two decades.
Starkey continues to be at the forefront of technology and innovation and is committed to collaborating with global researchers and innovators. A recent peer-reviewed article, published in Otology & Neurotology, highlights the collaborative research...
Prolific Machines, a biotechnology company using light to control biology, announces the appointment of Christina Perry to its expert team. Christina Perry joins Prolific as CFO where she will be charged with scaling Prolific's growth and financial...
Sage Growth Partners (Sage), a healthcare growth strategy and marketing firm with deep expertise in market research, go-to market strategy, and marketing communications, has partnered with GroundGame.Health, a social impact company, to release new...
Aspen Dental® has teamed up with Ivoclar, a global pioneer in dental innovation, to introduce the Signature Elite Denture, a breakthrough in patient care that blends accessibility, precision, and innovation. The companies have been working together...
The National Resident Matching Program® (NRMP®) has published Results and Data: Specialties Matching Service® 2025 Appointment Year for Fellowship Matches in the Specialties Matching Service® (SMS®). The report is an important compendium reflecting...
Report on how AI is driving market transformation - The elderberry market and it is set to grow by USD 349.5 million from 2025 to 2029. However, the growth momentum will progressing at a CAGR of 7.6% during the forecast period, according to...